Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Dey, Antu K ^a   Burke, Brian ^a   Sun, Yide ^a   Sirokman, Klara ^a   Nandi, Avishek ^a   Hartog, Karin ^a   Lian, Ying ^a,d   Geonnotti, Anthony R ^b   Montefiori, David ^b   Franti, Michael ^a,e   Martin, Grégoire ^c   Carfi, Andrea ^a   Kessler, Pascal ^c   Martin, Loïc ^c   Srivastava, Indresh K ^a,f   Barnett, Susan W ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^d GILEAD SCIENCES   (United States)

^e BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^f VRC/NIAI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CHEMOKINE RECEPTOR CCR5; EPITOPE; GLYCOPROTEIN GP 140; HIV 1 ENVELOPE GLYCOPROTEIN; MINI CD4 PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; CD4 ANTIGEN; CROSS LINKING REAGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; COMPLEX FORMATION; FEMALE; GENETIC LINKAGE; NONHUMAN; PROTEIN STABILITY; PROTEIN STRUCTURE; RABBIT; RECEPTOR BINDING; VIRUS INFECTION; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY PRODUCTION; BIOMIMETICS; CHEMISTRY; DRUG EFFECT; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; METABOLISM; SERODIAGNOSIS; SYNTHESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIGENS, CD4; BIOMIMETICS; CROSS-LINKING REAGENTS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; FEMALE; HIV ANTIBODIES; HIV-1; IMMUNIZATION; NEUTRALIZATION TESTS; RABBITS; RECOMBINANT PROTEINS;

EID: 84856152933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030233     Document Type: Article

References (71)

1. Walker BD, Burton DR, (2008) Toward an AIDS vaccine. Science 320: 760-764.
2. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
3. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
4. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
5. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
6. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
7. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
8. Forsell MN, Schief WR, Wyatt RT, (2009) Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 4: 380-387.
9. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540.
10. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
11. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
12. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123-1127.
13. Douek DC, Kwong PD, Nabel GJ, (2006) The rational design of an AIDS vaccine. Cell 124: 677-681.
14. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, et al. (2005) Comparing antigenicity and immunogenicity of engineered gp120. J Virol 79: 12148-12163.
15. Pantophlet R, Wilson IA, Burton DR, (2003) Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 77: 5889-5901.
16. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L, (2003) Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 77: 2310-2320.
17. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565.
18. Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, et al. (2002) Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 99: 11842-11847.
19. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 104: 17477-17482.
20. Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, et al. (2005) Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies 14: 101-113.
21. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, et al. (2006) Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80: 8745-8762.
22. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196.
23. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, et al. (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201: 1407-1419.
24. Vaine M, Wang S, Hackett A, Arthos J, Lu S, Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28: 2999-3007.
25. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, et al. (2011) A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. J Infect Dis 203: 1165-1173.
26. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, et al. (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21: 71-76.
27. Martin G, Burke B, Thai R, Dey AK, Combes O, et al. (2011) Stabilization of HIV-1 envelope in the CD4-bound conformation through specific crosslinking of a CD4 mimetic. J Biol Chem.
28. Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, et al. (2008) CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 61: 818-826.
29. Stricher F, Huang CC, Descours A, Duquesnoy S, Combes O, et al. (2008) Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J Mol Biol 382: 510-524.
30. Dey AK, Khati M, Tang M, Wyatt R, Lea SM, et al. (2005) An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 79: 13806-13810.
31. Farzan M, Vasilieva N, Schnitzler CE, Chung S, Robinson J, et al. (2000) A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem 275: 33516-33521.
32. Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, et al. (2003) Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77: 11244-11259.
33. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, et al. (2002) Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 76: 2835-2847.
34. Dey AK, David KB, Klasse PJ, Moore JP, (2007) Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360: 199-208.
35. Martin G, Sun Y, Heyd B, Combes O, Ulmer JB, et al. (2008) A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide. Virology 381: 241-250.
36. Montefiori DC, (2009) Measuring HIV neutralization in a luciferase reporter gene assay Humana Press pp. 395-405.
37. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
38. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, et al. (2009) Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83: 1045-1059.
39. Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, et al. (2008) N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology 372: 187-200.
40. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD, (1992) Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 66: 235-243.
41. Burke B, Gomez-Roman VR, Lian Y, Sun Y, Kan E, et al. (2009) Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 387: 147-156.
42. Pinter A, (2007) Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr HIV Res 5: 542-553.
43. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, et al. (1990) Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 64: 5701-5707.
44. Thali M, Olshevsky U, Furman C, Gabuzda D, Li J, et al. (1991) Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol 65: 5007-5012.
45. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, et al. (1991) Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 65: 6188-6193.
46. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978-3988.
47. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE, (2002) Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 18: 1207-1217.
48. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, et al. (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83: 8925-8937.
49. Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, et al. (2006) Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 24: 4995-5002.
50. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
51. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
52. Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, et al. (2009) Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 106: 3952-3957.
53. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458: 636-640.
54. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, et al. (2002) A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76: 644-655.
55. Forsell MN, Dey B, Morner A, Svehla K, O'Dell S, et al. (2008) B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog 4: e1000171.
56. Varadarajan R, Sharma D, Chakraborty K, Patel M, Citron M, et al. (2005) Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J Virol 79: 1713-1723.
57. He Y, D'Agostino P, Pinter A, (2003) Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine 21: 4421-4429.
58. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, et al. (2009) Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 5: e1000445.
59. Cherpelis S, Shrivastava I, Gettie A, Jin X, Ho DD, et al. (2001) DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 75: 1547-1550.
60. Buckner C, Gines LG, Saunders CJ, Vojtech L, Srivastava I, et al. (2004) Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320: 167-180.
61. Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, et al. (2006) Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22: 1022-1030.
62. Barnett SW, Burke B, Sun Y, Kan E, Legg H, et al. (2010) Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 84: 5975-5985.
63. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, et al. (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3: 651-658.
64. Bogers WM, Davis D, Baak I, Kan E, Hofman S, et al. (2008) Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382: 217-225.
65. Hu SL, Travis BM, Stallard V, Abrams K, Misher L, et al. (1992) Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection. AIDS Res Hum Retroviruses 8: 1489-1494.
66. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, et al. (1992) Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255: 456-459.
67. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, et al. (2008) Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Aids 22: 339-348.
68. Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, et al. (1999) Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J Virol 73: 3292-3300.
69. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
70. Haynes B, Case Control Study of the RV144 Trial for Immune Correlates: The Analysis and Way Forward; 2011; Bangkok, Thailand.
71. Lewis GK, Fouts TR, Ibrahim S, Taylor BM, Salkar R, et al. (2011) Identification and Characterization of an Immunogenic Hybrid Epitope Formed by both HIV gp120 and Human CD4 Proteins. J Virol 85: 13097-13104.